Bluestone Resources Inc 주식 (OTC: BBSRF)

에 대한 최신 뉴스 Bluestone Resources Inc (OTC:BBSRF) 주식

Forex,Currency,Trading,Concept.,Financial,Markets,And,Global,Economy,Concept.

$BTC

BBSRF

BMWYY

European Aeronautic Defence And Space Unsponsored

EADSY

ORAN

PPRUY

NOVO

미국 주식 시장이 노동절 연휴로 인해 문을 닫으면서 거래량이 적어 9월에는 글로벌 시장이 조심스럽게 시작되었다.
트레이더들이 유럽중앙은행(ECB)의 임박한 금리 인하를 예상함에 따라 유럽 시장은 소폭 상승 마감했다. 범유럽 유로 스톡스 50 지수는 이날 0.3% 상승해 7월 중순 이후 최고 수준으로 마감했다. 독일에서는 DAX 지수가 0.1% 상승하며 종가 기준으로 새로운 기록을 세웠다.

美 노동절에 유럽 주식은 보합, 독일 DAX는 기록적인 마감, 천연가스 선물은 상승

Bluestone Resources Inc

<p>Hawaiian Electric Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) reported quarterly earnings of $0.23 per share which met the analyst consensus estimate. This is a 11.54 percent decrease over earnings of $0.26 per share from the same period last year.  The company reported $744.07 million in sales this quarter. This is a 6.05 percent decrease over sales of $792.01 million the same period last year.</p>


Earnings

News

Hawaiian Electric Indus Q1 Adj. EPS $0.23, Inline, Sales $744.07M Down From $792.01M YoY

<p>HF Foods Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFFG#NASDAQ">HFFG</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate HF Foods Group to report an <strong>earnings per share</strong> (EPS) of $0.13.</p>
<p>HF Foods Group bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<p>Here's a look at HF Foods Group's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.11</td>
<td>-0.07</td>
<td>0</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>28.999999999999996%</td>
<td>-1.0%</td>
<td>3.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Market Performance of HF Foods Group's Stock</h3>
<p>Shares of HF Foods Group were trading at $3.9 as of May 08. Over the last 52-week period, shares are up 43.04%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/HFFG/earnings"><strong>To track all earnings releases for HF Foods Group visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


HFFG

A Look Ahead: HF Foods Group's Earnings Forecast

<p>Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) today announced that its board of directors declared a quarterly cash dividend of 67 cents per share of common stock, which reflects the company's earnings growth and strong cash generation. The dividend is payable on June 30, 2025, to shareholders of record as of the close of business on May 23, 2025.</p>


Dividends

Marriott International Raises Quarterly Cash Dividend From $0.63 To $0.67 Per Share

<p>FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate FiscalNote Holdings to report an <strong>earnings per share</strong> (EPS) of $-0.04.</p>
<p>Investors in FiscalNote Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company missed EPS by $0.06, which was followed by a 4.38% drop in the share price the next day.</p>
<p>Here's a look at FiscalNote Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.04</td>
<td>-0.10</td>
<td>0.01</td>
<td>-0.17</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.10</td>
<td>-0.11</td>
<td>-0.09</td>
<td>-0.12</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>-13.0%</td>
<td>-4.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821195_0.png" alt="eps graph" /></p>
<h3>Market Performance of FiscalNote Holdings's Stock</h3>
<p>Shares of FiscalNote Holdings were trading at $0.6437 as of May 08. Over the last 52-week period, shares are down 55.04%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Insights Shared by Analysts on FiscalNote Holdings</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding FiscalNote Holdings.</p>
<p>With 5 analyst ratings, FiscalNote Holdings has a consensus rating of Buy. The average one-year price target is $2.7, indicating a potential 319.45% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of  and RCM Technologies, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for RCM Technologies, with an average 1-year price target of $30.0, suggesting a potential 4560.56% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for  and RCM Technologies, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>FiscalNote Holdings</td>
<td>Buy</td>
<td>-14.00%</td>
<td>$19.40M</td>
<td>-13.63%</td>
</tr>
<tr>
<td>RCM Technologies</td>
<td>Buy</td>
<td>8.28%</td>
<td>$21.57M</td>
<td>9.03%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>FiscalNote Holdings ranks lower in Revenue Growth compared to its peers. It also lags behind in Gross Profit margin. However, it outperforms in Consensus rating and Return on Equity.</p>
<h3>All You Need to Know About FiscalNote Holdings</h3>
<p>FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.</p>
<h3>FiscalNote Holdings: A Financial Overview</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Challenges:</strong> FiscalNote Holdings's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-14.0%</strong>. This indicates a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-45.41%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> FiscalNote Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-13.63%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> FiscalNote Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-4.03%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> FiscalNote Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.77</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/NOTE/earnings"><strong>To track all earnings releases for FiscalNote Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


NOTE

A Peek at FiscalNote Holdings's Future Earnings

<p><strong>On May 5, 2025, the Audit Committee (the "Audit Committee") of the Board of Directors of Digital Ally, Inc. (the "Company") approved the dismissal of RBSM LLP ("RBSM") as the Company's independent registered public accounting firm.</strong></p>
<p>&nbsp;</p>
<p><strong>The reports of RBSM on the Company's consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that RBSM's reports on the consolidated financial statements of the Company as of and for the years December 31, 2024 contained an explanatory paragraph stating that "The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has incurred substantial operating losses and will require additional capital to continue as a going concern. This raises substantial doubt about the Company's ability to continue as a going concern. Management's plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty."</strong></p>
<p>&nbsp;</p>
<p><strong>During the fiscal years ended December 31, 2024 and 2023, and through May 5, 2025, there have been no "disagreements" (as defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions) with RBSM on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements if not resolved to the satisfaction of RBSM would have caused RBSM to make reference thereto in its reports on the consolidated financial statements for such years. During the fiscal years ended December 31, 2024 and 2023, and through May 5, 2025, there have been no "reportable events" (as defined in Item 304(a)(1)(v) of Regulation S-K).</strong></p>
<p>&nbsp;</p>
<p><strong>The Company provided RBSM with a copy of the disclosure it is making herein in response to Item 304(a) of Regulation S-K, and requested that RBSM to furnish the Company with a copy of its letter addressed to the Securities and Exchange Commission (the "SEC"), pursuant to Item 304(a)(3) of Regulation S-K, stating whether or not RBSM agrees with the statements related to them made by the Company in this report. A copy of RBSM's letter to the SEC dated May 7, 2025 is attached as Exhibit 16.1 to this report.</strong></p>
<p>&nbsp;</p>
<p><strong>(b) Appointment of New Independent Registered Public Accounting Firm</strong></p>
<p>&nbsp;</p>
<p><strong>On May 5, 2025, the Audit Committee approved the appointment of Victor Mokuolu CPA PLLC ("Mokuolu") as the Company's new independent registered public accounting firm, effective immediately, to perform independent audit services for the fiscal year ending December 31, 2025. During the fiscal years ended December 31, 2024 and 2023 and through May 5, 2025, neither the Company, nor anyone on its behalf, consulted Mokuolu regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to the consolidated financial statements of the Company, and no written report or oral advice was provided to the Company by Mokuolu that was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a "disagreement" (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a "reportable event" (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).</strong></p>


DGLY

Digital Ally Replaces Auditor RBSM With Victor Mokuolu CPA Despite No Disputes, Amid Going Concern Warning

<p><strong>FibroGen</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that FibroGen will report an <strong>earnings per share</strong> (EPS) of $-0.10. </p>
<p>The market awaits FibroGen's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS beat by $0.12, leading to a 21.8% drop in the share price on the subsequent day.</p>
<p>Here's a look at FibroGen's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.20</td>
<td>-0.30</td>
<td>-0.26</td>
<td>-0.42</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.08</td>
<td>-0.17</td>
<td>-0.16</td>
<td>-0.33</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-22.0%</td>
<td>-14.000000000000002%</td>
<td>5.0%</td>
<td>18.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821173_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of FibroGen were trading at $0.3194 as of May 08. Over the last 52-week period, shares are down 74.54%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/FGEN/earnings"><strong>To track all earnings releases for FibroGen visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


FGEN

A Preview Of FibroGen's Earnings

<p>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Coherus BioSciences will report an <strong>earnings per share</strong> (EPS) of $-0.15.</p>
<p>Investors in Coherus BioSciences are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS missed by $0.15 in the last quarter, leading to a 0.96% increase in the share price on the following day.</p>
<p>Here's a look at Coherus BioSciences's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.13</td>
<td>-0.12</td>
<td>-0.16</td>
<td>-0.24</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.28</td>
<td>-0.01</td>
<td>-0.14</td>
<td>-0.32</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>13.0%</td>
<td>11.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821155_0.png" alt="eps graph" /></p>
<h3>Performance of Coherus BioSciences Shares</h3>
<p>Shares of Coherus BioSciences were trading at $0.9923 as of May 08. Over the last 52-week period, shares are down 53.6%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CHRS/earnings"><strong>To track all earnings releases for Coherus BioSciences visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CHRS

Earnings Preview: Coherus BioSciences

WIIM

FSLR

SEDG

Shares of solar stocks are trading higher following a report suggesting Republican lawmakers support tax credits in former President Biden's Inflation Reduction Act legislation.

<p>Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Microvision will report an <strong>earnings per share</strong> (EPS) of $-0.06.</p>
<p>The announcement from Microvision is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company missed EPS by $0.05, which was followed by a 6.47% drop in the share price the next day.</p>
<p>Here's a look at Microvision's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.09</td>
<td>-0.10</td>
<td>-0.13</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.14</td>
<td>-0.07</td>
<td>-0.11</td>
<td>-0.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>3.0%</td>
<td>8.0%</td>
<td>-25.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821093_0.png" alt="eps graph" /></p>
<h3>Market Performance of Microvision's Stock</h3>
<p>Shares of Microvision were trading at $1.15 as of May 08. Over the last 52-week period, shares are down 3.2%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Opinions on Microvision</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Microvision.</p>
<p>A total of 4 analyst ratings have been received for Microvision, with the consensus rating being Buy. The average one-year price target stands at $2.5, suggesting a potential 117.39% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of  and SmartRent, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for SmartRent, with an average 1-year price target of $1.45, suggesting a potential 26.09% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>Within the peer analysis summary, vital metrics for  and SmartRent are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microvision</td>
<td>Buy</td>
<td>-67.65%</td>
<td>$-2.47M</td>
<td>-54.36%</td>
</tr>
<tr>
<td>SmartRent</td>
<td>Neutral</td>
<td>-18.11%</td>
<td>$13.56M</td>
<td>-14.88%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Microvision ranks lower in Revenue Growth compared to its peer. It also lags in Gross Profit and Return on Equity. Overall, Microvision's performance is below its peer in all key metrics analyzed.</p>
<h3>Discovering Microvision: A Closer Look</h3>
<p>Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.</p>
<h3>Financial Milestones: Microvision's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Microvision's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-67.65%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Microvision's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-1888.18%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Microvision's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-54.36%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Microvision's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-29.75%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Microvision's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.06</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/MVIS/earnings"><strong>To track all earnings releases for Microvision visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MVIS

Insights Ahead: Microvision's Quarterly Earnings

<p><strong>Assertio Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Assertio Holdings will report an <strong>earnings per share</strong> (EPS) of $-0.06. </p>
<p>Anticipation surrounds Assertio Holdings's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company beat EPS by $0.01, which was followed by a 7.46% drop in the share price the next day.</p>
<p>Here's a look at Assertio Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.04</td>
<td>-0.05</td>
<td>-0.03</td>
<td>-0.03</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.03</td>
<td>0.03</td>
<td>0.02</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>-8.0%</td>
<td>-12.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821078_0.png" alt="eps graph" /></p>
<h3>Assertio Holdings Share Price Analysis</h3>
<p>Shares of Assertio Holdings were trading at $0.6394 as of May 08. Over the last 52-week period, shares are down 41.89%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ASRT/earnings"><strong>To track all earnings releases for Assertio Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ASRT

A Look at Assertio Holdings's Upcoming Earnings Report

<p>Clarke (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CKI#TSX">CKI</a>) reported quarterly losses of $(0.17) per share. This is a 200 percent decrease over earnings of $0.17 per share from the same period last year.  The company reported $17.70 million in sales this quarter. This is a 21.23 percent increase over sales of $14.60 million the same period last year.</p>


TSX:CKI

Clarke Q1 EPS $(0.17) Down From $0.17 YoY, Sales $17.70M Up From $14.60M YoY

<p><strong>Landsea Homes</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Landsea Homes will report an <strong>earnings per share</strong> (EPS) of $-0.03. </p>
<p>Landsea Homes bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS missed by $0.22, leading to a 8.37% increase in the share price on the subsequent day.</p>
<p>Here's a look at Landsea Homes's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.47</td>
<td>0.15</td>
<td>0.10</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.25</td>
<td>0.44</td>
<td>0.36</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>8.0%</td>
<td>-2.0%</td>
<td>-7.000000000000001%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821024_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Landsea Homes were trading at $6.1 as of May 08. Over the last 52-week period, shares are down 34.83%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/LSEA/earnings"><strong>To track all earnings releases for Landsea Homes visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LSEA

An Overview of Landsea Homes's Earnings

<p><strong>Tango Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Tango Therapeutics will report an <strong>earnings per share</strong> (EPS) of $-0.38. </p>
<p>Investors in Tango Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.01, leading to a 5.05% drop in the share price the following trading session.</p>
<p>Here's a look at Tango Therapeutics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.34</td>
<td>-0.37</td>
<td>-0.34</td>
<td>-0.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.35</td>
<td>-0.27</td>
<td>-0.24</td>
<td>-0.35</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>-13.0%</td>
<td>2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821016_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Tango Therapeutics were trading at $1.1 as of May 08. Over the last 52-week period, shares are down 84.47%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Insights on Tango Therapeutics</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Tango Therapeutics.</p>
<p>Analysts have given Tango Therapeutics a total of 1 ratings, with the consensus rating being Buy. The average one-year price target is $13.0, indicating a potential 1081.82% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of  and Tonix Pharmaceuticals, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for  and Tonix Pharmaceuticals, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tonix Pharmaceuticals</td>
<td>Outperform</td>
<td>-31.67%</td>
<td>$1.40M</td>
<td>-20.68%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Tango Therapeutics ranks at the bottom among its peers in terms of consensus rating. It also lags behind in revenue growth and gross profit. Additionally, its return on equity is lower compared to its peers.</p>
<h3>Discovering Tango Therapeutics: A Closer Look</h3>
<p>Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.</p>
<h3>Financial Insights: Tango Therapeutics</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Tango Therapeutics faced challenges, resulting in a decline of approximately <strong>-24.19%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Tango Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-914.99%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Tango Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-17.57%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-11.26%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Tango Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.18</strong>.</p>
<p><a href="https://www.benzinga.com/quote/TNGX/earnings"><strong>To track all earnings releases for Tango Therapeutics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TNGX

Insights into Tango Therapeutics's Upcoming Earnings

<p>Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Blink Charging will report an <strong>earnings per share</strong> (EPS) of $-0.12.</p>
<p>Blink Charging bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS beat by $0.01 in the last quarter, leading to a 5.99% increase in the share price on the following day.</p>
<p>Here's a look at Blink Charging's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.16</td>
<td>-0.16</td>
<td>-0.15</td>
<td>-0.24</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.15</td>
<td>-0.16</td>
<td>-0.18</td>
<td>-0.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>-17.0%</td>
<td>-15.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820993_0.png" alt="eps graph" /></p>
<h3>Market Performance of Blink Charging's Stock</h3>
<p>Shares of Blink Charging were trading at $0.8366 as of May 08. Over the last 52-week period, shares are down 73.5%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BLNK/earnings"><strong>To track all earnings releases for Blink Charging visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BLNK

Insights into Blink Charging's Upcoming Earnings

<p><strong>Target Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) stock has slumped 29% so far this year, extending declines after falling in each of the last three years. The seventh biggest US retailer has seen a whopping two-thirds of its market value eroded since peaking just above $129 billion in mid-2021. Fast forward to 2025, and its market capitalization is just about $44 billion.</p>
<p>Target&#8217;s steep and extended declines in the stock market potentially serves as a <a href="https://www.benzinga.com/etfs">warning for ETF investors</a> who still think highly of big-box retail.</p>
<p><strong>What Does This Mean For ETFs?</strong></p>
<ul class="wp-block-list">
<li><strong>Retail ETFs: Risk In The Aisles</strong></li>
</ul>
<p>For funds invested in Target such as the <strong>VanEck Retail ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTH#NASDAQ">RTH</a>), the retailer&#8217;s poor market performance has been a drag. A once-safe bet on middle-class spending, Target now embodies the agony of inflation-weary shoppers and the boundaries of retail automatization.</p>
<ol class="wp-block-list">
<li></li>
</ol>
<p>With peers such as <strong>Macy&#8217;s </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) also hinting at strain, these ETFs are as much at the mercy of changing U.S. consumer risks as ever.</p>
<ul class="wp-block-list">
<li><strong>Dividend ETFs: Is The Yield Worth The Risk?</strong></li>
</ul>
<p>Target continues to boast a 4.66% dividend yield, underpinned by a history of <a href="https://www.benzinga.com/quote/TGT/dividends">annual dividend increases</a>. That&#8217;s left it securely in the portfolio of <strong>VictoryShares Dividend Accelerator ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSDA#NASDAQ">VSDA</a>).</p>
<ol start="2" class="wp-block-list">
<li></li>
</ol>
<p>But be warned: Target&#8217;s dividend record may be strong, but without earnings growth or investor confidence, that won&#8217;t redeem the stock&#8217;s weakness.</p>
<p><strong>What&#8217;s Happening With TGT?</strong></p>
<ol start="3" class="wp-block-list">
<li></li>
</ol>
<p>In early 2025, when Target announced a rollback of its Diversity, Equity, and Inclusion (DEI) initiatives, it sparked criticism and a 40-day boycott by consumers. That pushed Target&#8217;s stock down further till it lost about $12.4 billion in market value by February.</p>
<p>Then came the class-action lawsuit following the backlash, which accused Target of misleading investors about the risks of changing its DEI policies. </p>
<p>It didn&#8217;t end there. That was followed by uncertainty over Target&#8217;s policy on self-checkout lanes. Media reports this week hinted that Target is limiting self-checkout to thwart shoplifting. But the company says it&#8217;s merely enforcing a 10-items-or-fewer rule—a policy it rolled out quietly in March 2024, not last weekend. But the confusion adds to the image of a company grappling to fill gaps while navigating turbulent macro seas.</p>
<p>Now, with customer worries about theft, &#8220;shrink,&#8221; and subpar customer experience, the sheen of tech-savvy retail is fading. A reminder that automation, poorly executed, can shrink more than products—it can lose consumer trust.</p>
<p>And now, amid fears that <a href="https://www.benzinga.com/news/global/25/04/45017240/covid-like-shortages-empty-shelves-expected-thanks-to-trump-tariffs-experts-say">U.S. tariffs on international trade will lead to empty shop shelves</a>, Target appears to be restocking investor anxiety more than customer baskets.</p>
<p>Adding more intrigue, Senator <strong>Shelley Moore Capito </strong>recently <a href="https://www.benzinga.com/insights/government/25/05/45290762/a-congress-member-sold-up-to-30k-in-target-stock-heres-what-you-need-to-know">sold TGT shares on May 7</a>, as reported under the STOCK Act. The range of value sold was $2,002 to $30,000. Although one congressional trade isn&#8217;t gospel, investors may consider this a subtle red flag.</p>
<p><strong>Final Receipt</strong></p>
<p>Target&#8217;s <a href="https://stockanalysis.com/stocks/tgt/market-cap/?utm_source=chatgpt.com">valuation </a>crash isn&#8217;t merely a corporate fall from favor—it might just be a flashing yellow warning light for ETF investors. If you&#8217;re in it for the dividends, sector exposure, or thematic play on retail disruption, it&#8217;s time to rethink what TGT does for your portfolio. As of today, this Target may be more of a moving one.</p>
<p><strong>Read Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/etfs/new-etfs/25/05/45319298/smart-hedged-and-contrarian-invescos-new-etfs-tackle-growth-risk-value-gaps">Smart, Hedged And Contrarian: Invesco&#8217;s New ETFs Tackle Growth, Risk, Value Gaps</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>



Equities

Sector ETFs

ETFs

Merrill Lynch Retail HOLDRS Trust due 12/31/41

VSDA

Target's Self-Checkout Flip-Flop Isn't Helping After A 66% Value Crash: Are Retail ETFs Ringing Up The Real Risk?

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>D-Wave Quantum</strong>.</p>
<p>Looking at options history for D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) we detected 64 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 29% of the investors opened trades with bullish expectations and 40% with bearish.</p>
<p>From the overall spotted trades, 51 are puts, for a total amount of $2,138,942 and 13, calls, for a total amount of $674,235.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $8.0 to $15.0 for D-Wave Quantum during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for D-Wave Quantum options trades today is 3352.44 with a total volume of 204,657.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for D-Wave Quantum's big money trades within a strike price range of $8.0 to $15.0 over the last 30 days.</p>
<h3>D-Wave Quantum Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820978_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>QBTS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.75</td>
<td>$1.65</td>
<td>$1.66</td>
<td>$11.00</td>
<td>$697.2K</td>
<td>319</td>
<td>4.5K</td>
</tr>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.6</td>
<td>$10.00</td>
<td>$112.0K</td>
<td>4.3K</td>
<td>435</td>
</tr>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$1.4</td>
<td>$1.35</td>
<td>$1.35</td>
<td>$10.00</td>
<td>$81.0K</td>
<td>6.5K</td>
<td>3.1K</td>
</tr>
<tr>
<td>QBTS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/23/25</td>
<td>$1.25</td>
<td>$1.15</td>
<td>$1.2</td>
<td>$11.00</td>
<td>$60.0K</td>
<td>103</td>
<td>618</td>
</tr>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/09/25</td>
<td>$1.2</td>
<td>$1.1</td>
<td>$1.1</td>
<td>$10.00</td>
<td>$55.0K</td>
<td>5.2K</td>
<td>3.8K</td>
</tr>
</tbody>
</table>
</p>
<h3>About D-Wave Quantum</h3>
<p>D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.</p>
<p>Having examined the options trading patterns of D-Wave Quantum, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>D-Wave Quantum's Current Market Status</h3>
<ul>
<li>With a trading volume of 154,363,182, the price of QBTS is up by 6.7%, reaching $11.12.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 90 days from now.</li>
</ul>
<h3>What Analysts Are Saying About D-Wave Quantum</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $13.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Needham persists with their Buy rating on D-Wave Quantum, maintaining a target price of $13. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for D-Wave Quantum, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

QBTS

This Is What Whales Are Betting On D-Wave Quantum

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Baidu</strong>.</p>
<p>Looking at options history for Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) we detected 9 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 44% of the investors opened trades with bullish expectations and 44% with bearish.</p>
<p>From the overall spotted trades, 4 are puts, for a total amount of $146,961 and 5, calls, for a total amount of $336,366.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $120.0 for Baidu during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Baidu stands at 858.0, with a total volume reaching 1,387.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Baidu, situated within the strike price corridor from $70.0 to $120.0, throughout the last 30 days.</p>
<h3>Baidu Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820973_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$11.7</td>
<td>$11.5</td>
<td>$11.5</td>
<td>$115.00</td>
<td>$136.8K</td>
<td>466</td>
<td align="right">120</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$5.9</td>
<td>$5.7</td>
<td>$5.9</td>
<td>$105.00</td>
<td>$95.8K</td>
<td>16</td>
<td align="right">652</td>
</tr>
<tr>
<td>BIDU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$2.71</td>
<td>$2.45</td>
<td>$2.52</td>
<td>$88.00</td>
<td>$43.5K</td>
<td>994</td>
<td align="right">228</td>
</tr>
<tr>
<td>BIDU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$5.05</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$90.00</td>
<td>$39.5K</td>
<td>137</td>
<td align="right">80</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$7.6</td>
<td>$7.55</td>
<td>$7.55</td>
<td>$85.00</td>
<td>$37.7K</td>
<td>1.3K</td>
<td align="right">98</td>
</tr>
</tbody>
</table>
</p>
<h3>About Baidu</h3>
<p>Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 72% of core revenue from online marketing services from its search engine in 2023. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.</p>
<p>After a thorough review of the options trading surrounding Baidu, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Baidu Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,791,618, the BIDU's price is up by 0.01%, now at $87.66. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 12 days.</li>
</ul>
<h3>Professional Analyst Ratings for Baidu</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $90.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Baidu, which currently sits at a price target of $90. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Baidu with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


BIDU

What the Options Market Tells Us About Baidu

<p><strong>Quipt Home Medical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QIPT#NASDAQ">QIPT</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Quipt Home Medical will report an <strong>earnings per share</strong> (EPS) of $0.02. </p>
<p>Quipt Home Medical bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.03, leading to a 2.32% drop in the share price the following trading session.</p>
<p>Here's a look at Quipt Home Medical's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0</td>
<td>0.01</td>
<td>-0.01</td>
<td>0.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.03</td>
<td>-0.07</td>
<td>-0.04</td>
<td>-0.03</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-15.0%</td>
<td>-18.0%</td>
<td>-14.000000000000002%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820972_0.png" alt="eps graph" /></p>
<h3>Quipt Home Medical Share Price Analysis</h3>
<p>Shares of Quipt Home Medical were trading at $2.14 as of May 08. Over the last 52-week period, shares are down 46.53%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/QIPT/earnings"><strong>To track all earnings releases for Quipt Home Medical visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


QIPT

Quipt Home Medical Earnings Preview

<p>Financial giants have made a conspicuous bullish move on Rocket Lab USA. Our analysis of options history for Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) revealed 18 unusual trades.</p>
<p>Delving into the details, we found 50% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $74,000, and 16 were calls, valued at $850,083.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $3.0 to $30.0 for Rocket Lab USA over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Rocket Lab USA options trades today is 3249.57 with a total volume of 6,746.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Rocket Lab USA's big money trades within a strike price range of $3.0 to $30.0 over the last 30 days.</p>
<h3>Rocket Lab USA Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820968_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.78</td>
<td>$1.66</td>
<td>$1.66</td>
<td>$22.00</td>
<td>$132.8K</td>
<td>1.7K</td>
<td align="right">914</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.8</td>
<td>$12.35</td>
<td>$12.8</td>
<td>$10.00</td>
<td>$102.4K</td>
<td>12.5K</td>
<td align="right">80</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$2.9</td>
<td>$2.89</td>
<td>$2.9</td>
<td>$20.00</td>
<td>$98.8K</td>
<td>2.2K</td>
<td align="right">404</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$6.4</td>
<td>$6.3</td>
<td>$6.33</td>
<td>$20.00</td>
<td>$63.3K</td>
<td>8.9K</td>
<td align="right">110</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.79</td>
<td>$2.73</td>
<td>$2.79</td>
<td>$20.00</td>
<td>$54.6K</td>
<td>5.1K</td>
<td align="right">578</td>
</tr>
</tbody>
</table>
</p>
<h3>About Rocket Lab USA</h3>
<p>Rocket Lab USA Inc is engaged in space, building rockets, and spacecraft. It provides end-to-end mission services that provide frequent and reliable access to space for civil, defense, and commercial markets. It designs and manufactures the Electron and Neutron launch vehicles and Photon satellite platform. Rocket Lab's Electron launch vehicle has delivered multiple satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. The business operates in two segments Launch Services and Space Systems. Geographically it serves Japan, Germany, rest of the world and earns key revenue from the United States.</p>
<p>After a thorough review of the options trading surrounding Rocket Lab USA, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Rocket Lab USA Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 27,429,557, with RKLB's price down by -10.41%, positioned at $20.7.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 90 days.</li>
</ul>
<h3>Professional Analyst Ratings for Rocket Lab USA</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $28.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $28. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Rocket Lab USA, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


RKLB

Market Whales and Their Recent Bets on RKLB Options

<p>GAN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAN#NASDAQ">GAN</a>) reported quarterly losses of $(0.15) per share. This is a 66.67 percent decrease over losses of $(0.09) per share from the same period last year.  The company reported quarterly sales of $29.37 million which missed the analyst consensus estimate of $35.88 million by 18.16 percent.  This is a 4.19 percent decrease over sales of $30.65 million the same period last year.</p>


Earnings Misses

GAN Q1 EPS $(0.15) Down From $(0.09) YoY, Sales $29.37M Miss $35.88M Estimate

Small Cap

Press Releases

Bluestone Appeals the Notification Received from the Guatemalan Ministry of Environment and Natural Resources

Aura Minerals to Acquire Bluestone Resources

Financing

Aura Minerals and Bluestone Resources Agree to Amendment to Arrangement Agreement

AURA MINERALS AND BLUESTONE RESOURCES AGREE TO AMENDMENT TO ARRANGEMENT AGREEMENT

Bluestone Announces the Filing of its Management Information Circular in Connection with its Special Meeting to Approve Acquisition by Aura

Bluestone Provides Update on its Special Meeting to Approve Acquisition by Aura

Bluestone Announces Securityholder Approval of the Plan of Arrangement at Special Meeting and Provides Transaction Update

Bluestone Obtains Final Order for Plan of Arrangement from the Supreme Court of British Columbia and Provides Transaction Update

Aura completes acquisition of Bluestone

ORAAF

TSX:ORA

TSXV:BSR

<p>미국 주식 시장이 <a href="https://www.benzinga.com/markets/equities/24/09/40674353/is-the-market-open-on-labor-day" target="_blank" rel="noopener" data-google-interstitial="false">노동절 연휴</a>로 인해 문을 닫으면서 거래량이 적어 9월에는 글로벌 시장이 조심스럽게 시작되었다.</p>
<p>트레이더들이 유럽중앙은행(ECB)의 임박한 금리 인하를 예상함에 따라 유럽 시장은 소폭 상승 마감했다. 범유럽 유로 스톡스 50 지수는 이날 0.3% 상승해 7월 중순 이후 최고 수준으로 마감했다. 독일에서는 DAX 지수가 0.1% 상승하며 종가 기준으로 새로운 기록을 세웠다.</p>
<p>유럽 ​​대형주 중에서는 <strong>사노피</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)가 3.6% 상승하며 상승세를 주도했고, <strong>오렌지</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORAN#NYSE">ORAN</a>)와 <strong>텔레포니카 SA</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEF#NYSE">TEF</a>)가 각각 1.7%, 1.5% 상승하며 뒤를 이었다.</p>
<p>가장 큰 하락폭을 기록한 종목은 <strong>에어버스 SE</strong>(OTCPK:EADSY)로 1.4% 하락했고 <strong>아디다스 AG</strong>(OTCPK:ADDY)는 0.9% 하락했으며 <strong>케어링 SA</strong>(OTCPK:PPRUY)와 <strong>BMW AG</strong>(OTCPK:BMWYY)는 각각 0.8% 하락했다.</p>
<h3 class="wp-block-heading">다른 시장들</h3>
<p>외환시장에서는 미 동부 시간 오후 2시 기준 유로화는 달러 대비 0.2% 오른 1.1070에 거래되며, 3일 연속 하락세를 끊었다. 영국 파운드는 달러 대비 0.1% 소폭 하락했고, 호주 달러는 0.4% 상승했다.</p>
<p>일본 엔화는 월요일 달러화 대비 0.4% 하락해 가장 약세를 보였으며, 연방준비제도(연준)의 공격적인 금리 인하 기대가 줄어들어 지난주 추세가 연장되었다.</p>
<p>원자재 시장에서 미국 천연가스 선물은 냉방 수요 증가로 인해 MBTU당 2.10달러로 2.8% 급등했다. 중서부 지역은 주말 동안 기록적인 기온에 직면해 6천만 명 이상의 주민에게 폭염 경보가 발령되고 에어컨 사용량이 급증했다.</p>
<p>원유 선물은 배럴당 0.5% 상승했고, 금은 온스당 2,498.91달러 아래로 약간 떨어지면서 0.2% 하락했다.</p>
<p><strong>비트코인</strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)은 일요일에 2.8% 하락한 후 58,550달러로 2% 이상 상승했다.</p>
<h3 class="wp-block-heading">월요일 주요 기업 뉴스</h3>
<ul>
<li>로이터통신에 따르면 독일 자동차 제조사 BMW가 전 세계 14만 대 이상의 자동차에 잠재적으로 영향을 미칠 수 있는 배터리 문제로 인해 전기 미니 쿠퍼 SE 차량을 리콜한다고 한다.</li>
<li>유럽 의약품청(EMA)이 월요일에 발표한 노트에서 네덜란드 제약회사 <strong>노보</strong> <strong>노디스크 A/S</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVO#NYSE">NOVO</a>)가 공급 상황이 안정될 때까지 신규 환자 등록을 계속 제한해야 한다고 권고했다. 이에 따라 노보 노디스크 주식은 1% 하락했다.</li>
<li>사모펀드 대기업 <strong>블랙스톤</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)가 <strong>버스톤 리소스</strong>(OTCPK:BBSRF)가 관리하는 유럽 물류 창고 포트폴리오의 80% 지분을 인수하기로 합의했다.</li>
</ul>
<p><em>추가로 읽어보세요:</em></p>
<ul>
<li><em><strong><a href="https://www.benzinga.com/24/09/40676774/september-market-seasonality-why-this-month-is-historically-the-toughest-for-investors">9월 시장 계절성: 왜 이 달이 역사적으로 투자자들에게 가장 힘든 달인가?</a></strong></em></li>
</ul>
<p><strong>다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요</strong><br />
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener"><strong>여기를 클릭</strong></a>하여 14일 무료 체험을 시작하세요.</p>

Comments

Bluestone Resources Inc

뉴스

에 대한 최신 뉴스 Bluestone Resources Inc (OTC:BBSRF) 주식

화요일, 9월 03, 2024

뉴스

파트너 / 기고자

벤징가 글로벌